The findings of the University of Colorado Department of Gynecologic Oncology's multicenter clinical trial were recently published in JAMA. CU Gynecologic Oncology Faculty looked to find out if there is an efficacious and safe oral treatment for thromboprophylaxis in postoperative patients with suspected gynecologic malignant neoplasms. Our findings, based on a randomized clinical trial which included 400 women, suggests that oral apixaban may offer a safe alternative to subcutaneous enoxaparin that is easier and less painful for patients to take.
Oral Apixaban Preferable for Preventing Postsurgery VTE in Patients With Gynecologic Cancer
Published:
These findings suggest that oral apixaban is a potentially safe, less painful, and easier-to-take alternative to subcutaneous enoxaparin for thromboprophylaxis after surgery for gynecologic cancer.Saketh Guntupalli, MD, et al.
Read on the Oncology Learning Network
Oral Apixaban Shows Safe, Beneficial Thrombosis Prevention Post-Surgery
Published:
In findings from a new study conducted by US investigators, apixaban provided safe, more tolerable, and easily-administered preventive care compared to subcutaneous enoxaparin for patients at risk of bleeding events following gynecologic cancer-related surgery.